Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MS-Ten is a brand name for an immediate-release oral formulation of morphine sulfate, a potent opioid analgesic derived from the opium poppy. It functions as a full agonist at the mu-opioid receptors (MOR) within the central nervous system, where it inhibits the release of nociceptive neurotransmitters and activates descending inhibitory pathways to provide profound analgesia. Morphine also interacts with kappa (KOR) and delta (DOR) opioid receptors, though with lower affinity. MS-Ten is specifically provided as a 10 mg tablet and is indicated for the management of acute and chronic pain that is severe enough to require an opioid and for which alternative analgesics are inadequate. Developed and manufactured by companies such as Atlantic Laboratories, it is a standard treatment in palliative care and for severe post-operative or trauma-related pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MS-Ten.